Press release
Brain Metastases Pipeline Outlook Report 2025: Key 40+ Companies and Breakthrough Therapies Shaping the Future Landscape
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Brain Metastases Pipeline Outlook Report [https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Brain Metastases Pipeline Report
* In August 2025, Grupo Espanol Multidisciplinar de Melanoma announced a Phase II clinical trial designed to evaluate the activity of encorafenib plus binimetinib followed by cemiplimab and fianlimab in patients with BRAF mutated melanoma and symptomatic brain metastases, following the simon design Two-stage minimax.
* In August 2025, Stemline Therapeutics Inc. conducted a study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in patients with active brain metastases from ER-positive, HER-2 negative breast cancer.
* DelveInsight's Brain Metastases pipeline report depicts a robust space with 40+ active players working to develop 45+ pipeline therapies for Brain Metastases treatment.
* The leading Brain Metastases Companies such as HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation and others.
* Promising Brain Metastases Pipeline Therapies such as GLIADEL, 18F fluciclovine, Pembrolizumab, IPILIMUMAB, Cabozantinib, Trastuzumab, capecitabine, lapatinib, Lenvatinib and others.
Learn how leading Brain Metastases Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ Brain Metastases Clinical Trials Assessment [https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Brain Metastases Emerging Drugs Profile
* ANG1005: Angiochem
ANG1005 is a novel targeted taxane derivative that is the first oncology product to leverage Angiochem's technology platform to cross the blood-brain barrier (BBB) and enter cancer cells. ANG1005 is an Angiopep-2 paclitaxel conjugate that gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the BBB. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain.
* Azeliragon: Cantex Pharmaceuticals, Inc.
Azeliragon, is an oral, small molecule, administered once-daily, that inhibits RAGE interactions with its natural ligands, including HMGB1 and S100 proteins, in the tumor microenvironment. Activation of RAGE by these ligands stimulates cancer and its progression and metastasis and resistance to cancer treatment.
* AZD3759: Alpha Biopharma Ltd.
Zorifertinib (AZD3759) is a type of reversible new generation EGFR TKI, which has a strong ability to penetrate the bloodstream, cerebrospinal fluid, and can reach blood volume in the tissue. It is currently investigated for brain metastases and completed Phase II/III trial in July 2022.
The Brain Metastases Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Brain Metastases with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Brain Metastases Treatment.
* Brain Metastases Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Brain Metastases Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Brain Metastases market.
From early-stage research to late-phase Brain Metastases Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed-download now! @ Brain Metastases Treatment Drugs [https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Brain Metastases Companies
HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation and others.
Brain metastases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Brain Metastases Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Stay updated with the latest Brain Metastases Pipeline Insights-download our report for a deep dive into the next generation of therapeutics! @ Brain Metastases Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Brain Metastases Pipeline Report
* Coverage- Global
* Brain Metastases Companies- HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation and others.
* Brain Metastases Pipeline Therapies- GLIADEL, 18F fluciclovine, Pembrolizumab, IPILIMUMAB, Cabozantinib, Trastuzumab, capecitabine, lapatinib, Lenvatinib and others.
* Brain Metastases Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Brain Metastases Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find answers in our latest Brain Metastases Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ Brain Metastases Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Brain metastases: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Brain metastases- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* ANG1005: Angiochem
* Mid Stage Products (Phase II)
* Paxalisib: Kazia Therapeutics
* Early Stage Products (Phase I)
* MW151: ImmunoChem Therapeutics, LLC
* Preclinical and Discovery Stage Products
* JBI-2174: Jubilant Therapeutics
* Inactive Products
* Brain metastases Key Companies
* Brain metastases Key Products
* Brain metastases- Unmet Needs
* Brain metastases- Market Drivers and Barriers
* Brain metastases- Future Perspectives and Conclusion
* Brain metastases Analyst Views
* Brain metastases Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=brain-metastases-pipeline-outlook-report-2025-key-40-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/brain-metastases-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Brain Metastases Pipeline Outlook Report 2025: Key 40+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4142778 • Views: …
More Releases from ABNewswire
Klondike Solitaire Card Games Drive Over $1.1 Million in Weekly Productivity Los …
OnlineCardGames.io released a data report showing that Klondike Solitaire Card Games account for a significant portion of lost work hours. The analysis reveals that these quick gaming sessions result in over $1.1 million in weekly costs to the national economy, peaking between mid-morning and early afternoon. If you have a specific character limit for the summary field, please let me know and I can adjust the length for you.
A recent…
Red Oak Hospice and Palliative Care: Providing Compassionate End-of-Life Care in …
In Bridgeton, NJ, Red Oak Hospice provides specialized hospice and palliative care, offering emotional support and tailored services for those facing end-of-life challenges.
Bridgeton, NJ - Red Oak Hospice and Palliative Care, a trusted provider of end-of-life care, remains committed to delivering compassionate, personalized care to patients and their families in the surrounding areas. Specializing in both hospice and palliative care Bridgeton NJ [https://redoakhospice.com/], we are committed to providing the highest…
The Boulder Group Arranges Sale of Net Leased Academy Sports + Outdoors within t …
The Boulder Group, a net leased investment brokerage firm completed the sale of a single tenant Academy Sports + Outdoors located at 9905 East US Highway 36 in Avon, IN for $10,800,000.
The 63,407-square-foot property is situated along US Highway 36, which sees more than 39,000 vehicles per day. It is positioned within a dense retail corridor featuring national tenants such as Lowe's, Target, Menards, Meijer, Costco, Walmart, ALDI, and others.…
TCL NXTPAPER 14 Brings Paper-Like Creativity to the Holidays
This holiday season, TCL is giving creators, students, and digital thinkers the perfect reason to swap their ordinary screens for something extraordinary. The TCL NXTPAPER 14 Android Tablet [https://www.amazon.com/dp/B0FLP554CZ?maas=maas_adg_D831E0B36DB2ED0E27C6CF6EAF4B3888_afap_abs&ref_=aa_maas&tag=maas], the company's flagship large-format device built around TCL's acclaimed eye-friendly NXTPAPER display, is now available at a special Christmas price of $299.99) 36% off MSRP $469.99) on Amazon [https://www.amazon.com/dp/B0FLP554CZ?maas=maas_adg_D831E0B36DB2ED0E27C6CF6EAF4B3888_afap_abs&ref_=aa_maas&tag=maas].
Image: https://www.abnewswire.com/upload/2025/12/eb108521b9945c6904a7b3466220a168.jpg
The NXTPAPER 14 is the culmination of TCL's vision to make digital…
More Releases for Brain
Brain Training Apps Market Boosting the Brain: The Rise of Brain Training Apps a …
Brain Training Apps Market Assessment worth $ 44.43 Billion by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Brain Training Apps Market- by App Type (Memory, Attention, Language, Executive Function, Visual/spatial, and Other App Types), User Type (Android, iOS and Other User Types), Trends, Industry Competition Analysis, Revenue and Forecast To 2024-2031."
Get a free sample copy of…
Nutrient Survival Champions Brain Health During Alzheimer's & Brain Awareness Mo …
This June, Nutrient Survival is reminding people that nourishing your mind is as crucial as feeding your body, offering a revolutionary BrainCare® line.
Reno, NV (June 5, 2024) - As June marks Alzheimer's & Brain Awareness Month, Nutrient Survival, veteran-led pioneer in nutritional innovation, stands at the forefront of promoting
cognitive well-being with its revolutionary BrainCare® line and Brain Omega 3 Bar®. With alarming statistics highlighting the prevalence of brain-related ailments among…
Brain Monitoring Device Market - Harnessing the Power of Neurotechnology: Brain …
Newark, New Castle, USA: The "Brain Monitoring Device Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Brain Monitoring Device Market: https://www.growthplusreports.com/report/brain-monitoring-device-market/7889
This latest report researches the industry structure,…
Supercharge Your Brain: Revolutionary Brain Health Supplements for Improved Brai …
The global 𝐁𝐫𝐚𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡 𝐒𝐮𝐩𝐩𝐥𝐞𝐦𝐞𝐧𝐭𝐬 market is estimated to attain a significant valuation by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand during the forecast period, 2021-2031.
The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of the Brain Health Supplements industry. The current…
Global Wearable Brain Devices Market Growth by 2030 - Advanced Brain Monitoring …
The research report based on the Global Wearable Brain Devices Industry offers the detailed study of each and every aspect coupled with the Wearable Brain Devices market. The report also analyzes all the strategic developments made in the Wearable Brain Devices sector. The research report offers detailed and accurate numerical data on costs, revenues, sales, profits, etc. The market report narrowly analyzes all the key growth factors that are considered…
Retro X Focus Nootropic Brain Booster - SUPERCHARGED BRAIN PERFORMANCE!
Retro X Focus Nootropic Brain Booster is a state-of-the-art nootropic that employs vitamins, vital nutrients, plus amino acids to assist you to think quicker, cleverer, smarten your memory, and improve attention and leave you feeling invigorated. The water-soluble extracts, which are useful in product additives, function to rejuvenate studying approaches and thinking.
Official Online Store - https://www.allnutritionhub.com/get-retro-x-focus-nootropic
How does the Retro X Focus Function?
It is common knowledge that we must work out…
